Finally, the results obtained by analyzing the effects of ISA-2011B on CD28-mediated upregulation of inflammatory IL-8, IL-6, and IL-17A genes in T lymphocytes from type 1 diabetes (T1D) patients suggest ISA-2011B as a promising anti-inflammatory drug. The gene discussed is IL17A; the disease is type 1 diabetes mellitus.